Chronic Myelopathies Associated with HTLV-I, A Clinical, Serologic, and Immunovirologic Study of 10 Patients in France
Arch Neurol 46:255-260, Gout,O.,et al, 1989
Cranial Magnetic Resonance Imaging in the Evaluation of Myelopathy of Undetermined Etiology
Neurol 37:840-843, Miska,R.M.,et al, 1987
Chronic Progressive Myelopathy:Investigation with CSF Electrophoresis, Evoked Potentials, & CT Scan
Ann Neurol 6:419-424, Patty,D.W.,et al, 1979
Multiple Sclerosis After Age 50
Neurol 33:1537-1544, Noseworthy,J.,et al, 1983
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000
Visual System Abnormalities in Adrenomyeloneuropathy
Ann Neurol 37:550-552, Kaplan,P.W.,et al, 1995
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Lidocaine Unmasks Silent Demyelinative Lesions in Multiple Sclerosis
Neurol 42:2088-2093, Sakurai,M.,et al, 1992
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Hallervorden-Spatz Syndrome and Brain Iron Metabolism
Arch Neurol 48:1285-1293, Swaiman,K.F., 1991
Vision and Hearing During Deferoxamine Therapy
J Pediatr 117:326-330, Cohen,A.,et al, 1990
Optic Neuritis:A Prospective Study
Neurol 40:919-923, Celesia,G.G.,et al, 1990
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978